James C Lanter

This inventor holds 34 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Selective Androgen Receptor Modulators. Top assignees: Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp., Other. Active years: 2003-2022.

USPTO Granted Patents = 34 (Patent Applications = 7)

% Patents Active = 44.1

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 8)

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 73(Granted Patents)

Location History:

Flemington, NJ (US) (2003 - 2004)
New Brunswick, NJ (US) (2004)
Hillsborough, NJ (US) (2003 - 2006)
Norristown, PA (US) (2009)
Exton, PA (US) (2011 - 2013)
Raritan, NJ (US) (2005 - 2014)
Spring House, PA (US) (2013 - 2014)
Audubon, PA (US) (2012 - 2021)
Cambridge, MA (US) (2022)

Company Filing History:

27 out of 2,099

Janssen Pharmaceutica Nv

patents

6 out of 363

Ortho-Mcneil Pharmaceutical Corp.

patents

1 out of 834,307

Other

patents

Years Active: 2003-2022

Loading Chart...

Areas of Expertise:

Selective Androgen Receptor Modulators

GPR120 Agonists

GPR40 Agonists

Type II Diabetes

CCR2 Antagonists

Phosphodiesterase Inhibitors

Neurotrophic Agents

Heterocycles

Benzimidazole Derivatives

Indole Derivatives

Cyclohexyl Compounds

Azetidine Derivatives

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11230526 - Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors (2022-01-25),

2. 10988433 - Cyclohexyl GPR40 agonists for the treatment of type II diabetes (2021-04-27),

3. 9434688 - Indole derivatives as selective androgen receptor modulators (SARMS) (2016-09-06),

4. 9120830 - 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) (2015-09-01),

5. 9062048 - Cyclohexyl-azetidinyl antagonists of CCR2 (2015-06-23),

6. 8921559 - 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 (2014-12-30),

7. 8802865 - 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) (2014-08-12),

8. 8765782 - Indole derivatives as selective androgen receptor modulators (SARMS) (2014-07-01),

9. 8586616 - Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) (2013-11-19),

10. 8575206 - 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS) (2013-11-05),

11. 8518969 - Cyclohexyl-azetidinyl antagonists of CCR2 (2013-08-27),

12. 8436023 - Cyclohexyl-azetidinyl antagonists of CCR2 (2013-05-07),

13. 8394971 - Indole derivatives as selective androgen receptor modulators (SARMS) (2013-03-12),

14. 8269015 - 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 (2012-09-18),

15. 7968580 - Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) (2011-06-28),

Title: The Innovative Journey of James C. Lanter

Introduction:

James C. Lanter, a distinguished inventor hailing from Raritan, NJ (US), has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents:

James C. Lanter holds several patents in various technological domains, including but not limited to telecommunications, software development, and renewable energy solutions.

Career Highlights:

With a career spanning over two decades, James C. Lanter has been at the forefront of innovation, consistently pushing the boundaries of what is possible in the tech industry. His work has not only revolutionized existing technologies but has also paved the way for future advancements.

Collaborations:

Throughout his career, James C. Lanter has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. His ability to work in multidisciplinary teams has led to the successful development and commercialization of several cutting-edge technologies.

Conclusion:

In conclusion, James C. Lanter's passion for innovation, coupled with his technical expertise, has established him as a prominent figure in the world of inventors. His relentless pursuit of excellence and commitment to pushing the boundaries of technology continue to inspire the next generation of innovators.